Regeneron Pharmaceuticals (NASDAQ:REGN) Director Kathryn Guarini Sells 400 Shares

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $320,000.00. Following the completion of the transaction, the director directly owned 603 shares of the company’s stock, valued at $482,400. This represents a 39.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $797.99 on Thursday. The firm has a market cap of $82.16 billion, a PE ratio of 19.72, a price-to-earnings-growth ratio of 1.36 and a beta of 0.22. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $821.11. The firm’s fifty day moving average is $668.89 and its 200-day moving average is $713.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same quarter in the previous year, the company posted $12.81 EPS. The business’s revenue was up 16.7% on a year-over-year basis. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be issued a $0.94 dividend. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 9.29%.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analyst commentary highlights continued growth from Eylea HD and Dupixent, along with progress in oncology and Regeneron’s broader pipeline. REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
• Positive Sentiment: Goldman Sachs maintained its Buy rating on Regeneron, reinforcing a constructive view of the company’s long-term prospects. Goldman Sachs Keeps Their Buy Rating on Regeneron
• Neutral Sentiment: Directors Huda Y. Zoghbi and Kathryn Guarini each sold shares at approximately $800 under pre-arranged Rule 10b5-1 trading plans. The transactions reduced their holdings by about 32% and 40%, respectively, but the plans lessen the signal that the sales reflect current views of Regeneron’s outlook. Director Sale Filing
• Negative Sentiment: Several law firms publicized a securities class action related to alleged investor harm and claims that Regeneron misled investors about the prospects of its Phase 3 fianlimab-Libtayo trial in advanced melanoma. The trial failure previously caused an approximately $11 billion market-value loss; the legal notices could sustain concern about litigation costs, disclosure practices and the oncology pipeline. The lead-plaintiff deadline is September 14, 2026. Regeneron Class Action Lawsuit Notice

Analysts Set New Price Targets

Several brokerages have issued reports on REGN. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research note on Tuesday, July 7th. Barclays dropped their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Cantor Fitzgerald increased their target price on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Royal Bank Of Canada raised their price target on shares of Regeneron Pharmaceuticals from $696.00 to $737.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st. Finally, Sanford C. Bernstein upgraded shares of Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $797.75.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. WPG Advisers LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 312.5% in the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 25 shares during the last quarter. SHP Wealth Management purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter worth about $26,000. Western Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the first quarter worth about $26,000. Titan Wealth CI Ltd bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth about $29,000. Finally, Mowery & Schoenfeld Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at about $29,000. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.